Albumin: Indications in chronic liver disease
- PMID: 32213034
- PMCID: PMC7268936
- DOI: 10.1177/2050640620910339
Albumin: Indications in chronic liver disease
Abstract
Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.
Keywords: Liver cirrhosis; acute kidney injury; ascites; hepatorenal syndrome; human albumin; paracentesis; spontaneous bacterial peritonitis.
Figures
References
-
- D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217–231. - PubMed
-
- European Association for the Study of the Liver (EASL) Clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. - PubMed
-
- Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatol 2003; 38: 258–266. - PubMed
-
- Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215–220. - PubMed
-
- Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatol 2002; 35: 140–148. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
